Detection of minimal residual disease in acute myeloid leukemia
- 1 October 2002
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 4 (5) , 398-402
- https://doi.org/10.1007/s11912-002-0033-z
Abstract
Acute myeloid leukemia (AML) is a curable malignancy, but its cure rate remains disappointingly low. Accurate quantitation of residual AML cells would allow individualization of therapy and thereby increase the likelihood of cure for each patient. Techniques that are being studied for residual disease detection include molecular assays for abnormalities that are present in subsets of AML patients, and multiparameter flow cytometry, which has broader applicability. Although significant advances have been made in the development of assays for monitoring residual disease, and particularly in techniques for molecular quantitation, additional refinement and validation are needed before these assays can be applied routinely in clinical management.Keywords
This publication has 28 references indexed in Scilit:
- Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable stateBlood, 2002
- Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemiaBlood, 2001
- Pre-Clinical Validation of a Novel, Highly Sensitive Assay to Detect PML-RARα mRNA Using Real-Time Reverse-Transcription Polymerase Chain ReactionThe Journal of Molecular Diagnostics, 2001
- Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specificLeukemia Research, 2001
- Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratificationBlood, 2001
- Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARα transcripts with a sensitive competitive RT-PCR methodLeukemia, 2001
- Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemiaLeukemia, 2001
- High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)Blood, 2001
- Detection and quantification ofCBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCRGenes, Chromosomes and Cancer, 2001
- Measurement of Residual Leukemia during Remission in Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1997